Natalizumab

Grey

Brand Name(s):Tysabri

Indication:Multiple Sclerosis

Rationale:2,5

Considered:Sep-07

Review Date:May-26

Comments:
NICE CG186 Updated guidance suggests treatment with other drug therapies
November 2019

Drug Safety Update
Progressive multifocal leukoencephalopathy—updated advice to support early detection
April 16
…………………………
Oct 2014
NICE CG186 Management of MS in Primary & Secondary Care:
http://www.nice.org.uk/guidance/cg186/resources/guidance-multiple-sclerosis-pdf
…………………………

MHRA Drug Safety Update Volume 3 Issue 8 March 2010

NICE technology appraisal August 2007 TA127